论文部分内容阅读
目的比较诺和锐30与诺和灵30R治疗初诊重症2型糖尿病的疗效,方法选取餐后2h血糖≥16mmoL/L的初诊重症2型糖尿病患者72例,随机分为诺和锐30组与诺和灵30R组,各组36例,采用2次/d早晚餐前皮下注射诺和锐30或诺和灵30R,治疗12周观察治疗前后7个时点血糖、糖化血红蛋白(HbA1c)、血糖达标所需天数、低血糖发生情况。结果两组患者在治疗12周后血糖、HbA1c均明显下降,7个时点血糖显示早、晚餐后2h、中餐前及睡前血糖控制效果,诺和锐30组明显优于诺和灵30R组(P<0.05),其他时点血糖无明显差异。两组间HbAlc差异无统计学意义(P>0.05)。血糖达标所需天数诺和锐30组显著少于诺和灵30R组(P<0.05)。诺和锐30组低血糖发生率显著低于诺和灵30R组(P<0.05)。结论对于初诊重症2型糖尿病患者,应用诺和锐30疗效优于诺和灵30R,且安全,依从性好。
Objective To compare the curative effect of Novo-Rui 30 and Novo-30R on newly diagnosed severe type 2 diabetes.Methods 72 patients with newly diagnosed type 2 diabetes mellitus with blood glucose> 16mmoL / L 2h after meal were randomly divided into Novo-Rui 30 and Novo He Ling 30R group, 36 cases in each group. The rats were anesthetized with Novolin 30 or Novolin 30R twice a day for 12 weeks before and after treatment. Blood glucose, HbA1c, The number of days required, the occurrence of hypoglycemia. Results After 12 weeks treatment, the blood glucose and HbA1c were significantly decreased in both groups. The blood glucose at 7 points was earlier and 2 hours after dinner, and the blood sugar control effect before and during pre-meal and Novo-Rui 30 was better than Novo-30R (P <0.05), no significant difference in other points of blood glucose. There was no significant difference in HbAlc between the two groups (P> 0.05). The number of days required for glycemic control was significantly lower in Nuo Rui Rui 30 group than in Noro Ling 30R group (P <0.05). The incidence of hypoglycemia in Novo Rui 30 group was significantly lower than that in NovoR 30R group (P <0.05). Conclusion For patients with newly diagnosed type 2 diabetes, Novo-Ruo30 is superior to Novo-30R in safety and compliance.